The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
Elevation Oncology to discontinue development of EO-3021, a Claudin 18.2 ADC to treat advanced unresectable or metastatic gastric and GEJ: Boston Saturday, March 22, 2025, 15:00 H ...
Vietnam Investment Review on MSN3d
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 for Platinum-resistant Ovarian CancerInnovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending ...
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
The placement and use of gastric tubes are one of the most common nursing procedures performed in the newborn intensive care unit (NICU). These tubes are used for gastric decompression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback